Buckle up, because the $NVAX setup we’ve been waiting for just got a massive catalyst. Today (Jan 20, 2026), Novavax announced a blockbuster licensing deal with Pfizer ($PFE) that is sending shares higher pre-market.
For the r/shortsqueeze crowd, this is the perfect "Fuel meets Match" scenario.
🚀 The "Big News" (The Catalyst)
Novavax just signed a licensing agreement for its Matrix-M adjuvant technology with Pfizer.
• The Cash: $30M upfront, with a path to $500M in milestone payments.
• The Residuals: Tiered high mid-single-digit royalties on all Pfizer sales using the tech.
• The Significance: Validation from the biggest player in the game. This provides a massive cash infusion and de-risks their balance sheet significantly.
The Squeeze Data (The Fuel):
This isn't just a "good news" play; the technical setup for a squeeze is primed:
• Short Interest: \~40.9% of the float is sold short (Source: Fintel/NASDAQ).
• Days to Cover: A massive 17 days. If this volume picks up, shorts will be tripping over each other for weeks to get out.
• Borrow Fee: Rates have been volatile, and with today's 5%+ pre-market jump, the pressure is mounting.
• Utilization: Historically high for NVAX, meaning there are very few shares left to borrow for new short positions.
📈 Technical Outlook:
• Current Price: \~$8.40 (Premarket)
• Next Resistance: $9.10 and then the 52-week high of $10.64.
• Price Target: Analysts have a median target of $12.00, but in a squeeze scenario, $15-$19 isn't out of the question given the 17-day cover time.
The Play:
The shorts have been betting on NVAX running out of cash. This Pfizer deal just killed that thesis. When the "long-term" shorts realize the bankruptcy risk is gone, they have to buy back 54 million shares.
High SI (40%), massive DTC (17 days), and a Pfizer partnership that just changed the fundamental story. This could be the runner of the week.
Disclaimer: Not financial advice. Biotech is volatile. Do your own DD.